Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Approves 23andMe Consumer Test for Hereditary CRC Syndrome

January 23rd 2019

The FDA has cleared a direct-to-consumer genetic test for a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome.

Bekaii-Saab Brings Insight to Precision Medicine in GI Cancers

January 23rd 2019

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Ibrutinib Combo Falls Short in Pancreatic Cancer

January 22nd 2019

The frontline combination of ibrutinib (Imbruvica) and nab-paclitaxel (Abraxane)/gemcitabine did not show a statistically significant benefit in progression-free or overall survival versus placebo plus nab-paclitaxel/gemcitabine in patients with metastatic pancreatic cancer.

Choti Sheds Light on Research Developments in Pancreatic Cancer

January 22nd 2019

Michael A. Choti, MD, highlights ongoing developments in the field of pancreatic cancer.

Dr. George on the Phase III TAGS Trial in Gastric/GEJ Cancer

January 22nd 2019

Ben George, MD, assistant professor, Medical College of Wisconsin, discusses the phase III TAGS trial in patients with gastric or gastroesophageal junction (GEJ) cancer.

Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD-1

January 22nd 2019

Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.

Study Supports TKI Response as Predictor of Survival in HCC

January 21st 2019

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

January 20th 2019

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

Single-Agent Durvalumab Elicits Responses in MSI-H CRC

January 20th 2019

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC

January 20th 2019

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer

January 20th 2019

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

January 19th 2019

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer

January 19th 2019

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer

January 19th 2019

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

Dr. Molena on Challenges With Endoscopic Resection in Esophageal Cancers

January 19th 2019

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

Analysis Sustains TAS-102 Survival Benefit in Gastric Cancer

January 19th 2019

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

Extending the Promise of Immunotherapy to Pancreatic Cancer

January 19th 2019

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

Dr. Noel on the Impact of SM-88 in Pancreatic Cancer

January 19th 2019

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

Ramucirumab/Nivolumab Combo Shows Potential in Advanced Gastric Cancer

January 18th 2019

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

Dr. Ocean on the Toxicities With SM-88 in Metastatic Pancreatic Cancer

January 18th 2019

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.